Last reviewed · How we verify

Metronidazole(MTZ) — Competitive Intelligence Brief

Metronidazole(MTZ) (Metronidazole(MTZ)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole antibiotic. Area: Infectious Disease.

phase 3 Nitroimidazole antibiotic Bacterial/parasitic DNA Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Metronidazole(MTZ) (Metronidazole(MTZ)) — Sherief Abd-Elsalam. Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced inside microbial cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Metronidazole(MTZ) TARGET Metronidazole(MTZ) Sherief Abd-Elsalam phase 3 Nitroimidazole antibiotic Bacterial/parasitic DNA
Metronidazole (BQ10) Metronidazole (BQ10) National Taiwan University Hospital marketed Nitroimidazole antibiotic Bacterial/parasitic DNA
Ornidazole and Sodium Chloride Injection Ornidazole and Sodium Chloride Injection Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd marketed Nitroimidazole antibiotic Bacterial/parasitic DNA
Metronidazole (ST14) Metronidazole (ST14) National Taiwan University Hospital marketed Nitroimidazole antibiotic Bacterial/parasitic DNA
Metronidazole 250 (14 days) Metronidazole 250 (14 days) University of Guarulhos marketed Nitroimidazole antimicrobial Bacterial/parasitic DNA
Metronidazole 400 (7 days) Metronidazole 400 (7 days) University of Guarulhos marketed Nitroimidazole antibiotic Bacterial/parasitic DNA
Metronidazole (Metrogel) Metronidazole (Metrogel) LEO Pharma marketed Nitroimidazole antibiotic Bacterial/parasitic DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitroimidazole antibiotic class)

  1. National Taiwan University Hospital · 2 drugs in this class
  2. Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · 2 drugs in this class
  3. University of Guarulhos · 2 drugs in this class
  4. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
  5. LEO Pharma · 1 drug in this class
  6. Sherief Abd-Elsalam · 1 drug in this class
  7. University of Alabama at Birmingham · 1 drug in this class
  8. University of Sao Paulo · 1 drug in this class
  9. Appili Therapeutics Inc. · 1 drug in this class
  10. bioRASI, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metronidazole(MTZ) — Competitive Intelligence Brief. https://druglandscape.com/ci/metronidazole-mtz. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: